Cancer treatment reports最新文献_第4页

Controlled clinical trial of doxorubicin and tamoxifen versus doxorubicin alone in hepatocellular carcinoma. 阿霉素联合他莫昔芬与阿霉素单用治疗肝细胞癌对照临床试验。

Cancer treatment reports Pub Date : 1987-12-01

W M Melia, P J Johnson, R Williams

引用次数: 0

Etoposide, ifosfamide, and cisplatin in the treatment of advanced non-small cell lung cancer. 依托泊苷、异环磷酰胺和顺铂治疗晚期非小细胞肺癌。

Cancer treatment reports Pub Date : 1987-12-01

A Ardizzoni, V Fusco, M Gulisano, P Pronzato, F Baracco, A Capaccio, G Pastorino, M Nosenzo, R Felletti, F Fabiano

引用次数: 0

Preclinical toxicology studies of 4-ipomeanol: a novel candidate for clinical evaluation in lung cancer. 4-异美酚的临床前毒理学研究:肺癌临床评价的新候选药物。

Cancer treatment reports Pub Date : 1987-12-01

A C Smith, D Barrett, M A Stedham, M el-Hawari, M D Kastello, C K Grieshaber, M R Boyd

{"title":"Preclinical toxicology studies of 4-ipomeanol: a novel candidate for clinical evaluation in lung cancer.","authors":"A C Smith, D Barrett, M A Stedham, M el-Hawari, M D Kastello, C K Grieshaber, M R Boyd","doi":"","DOIUrl":"","url":null,"abstract":"4-Ipomeanol (ipomeanol) is being developed as a potential antitumor agent to treat lung cancer. Ipomeanol produced a dose-related toxicity in CD2F1 mice, Fischer 344 rats, and beagle dogs. The LD50 in mice after a single iv dose of ipomeanol was 35 mg/kg in males and 26 mg/kg in females. Minimal cumulative toxicity occurred in mice after seven doses; LD50 was 30 mg/kg/day in males and 21 mg/kg/day in females. In rats, iv doses greater than or equal to 15 mg/kg were lethal. Labored respiration, terminal bronchiolar epithelial necrosis, interstitial inflammation, and alveolar edema were present in rats dosed with ipomeanol at greater than or equal to 9 mg/kg. In addition to pulmonary lesions, splenic and thymic lymphocyte depletion and/or necrosis was present. Ipomeanol had little cumulative toxicity in rats given seven daily doses. In dogs, iv doses greater than 12 mg/kg were lethal. Dogs treated with lethal doses of ipomeanol showed rapid, shallow respiration and pulmonary edema prior to death; diffuse pulmonary congestion or hemorrhage and diffuse renal congestion were present at necropsy. Pulmonary microscopic changes caused by nonlethal doses of ipomeanol included subacute interstitial inflammation and necrosis of respiratory bronchiolar and alveolar duct epithelium. In contrast to rodents, seven daily doses of ipomeanol were cumulatively toxic in dogs. The nonlethal pulmonary effects of ipomeanol were reversible in all three species. Tolerance to lethal doses of ipomeanol occurred in animals of all three species pretreated with multiple nontoxic doses of the drug. The LD50 of ipomeanol in male and female mice increased 2.4- and 4.5-fold, respectively, in tolerant mice. In rats and dogs, previously lethal doses of 48 and 24 mg/kg were nonlethal after tolerance was induced by pretreatment with seven daily doses of ipomeanol.","PeriodicalId":9581,"journal":{"name":"Cancer treatment reports","volume":"71 12","pages":"1157-64"},"PeriodicalIF":0.0,"publicationDate":"1987-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"14809710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cisplatin, doxorubicin, and cyclophosphamide (PAC) in the treatment of mixed mesodermal tumor of the ovary. 顺铂、阿霉素和环磷酰胺治疗卵巢混合性中胚层肿瘤的疗效观察。

Cancer treatment reports Pub Date : 1987-12-01

J Wheelock, K Hancock, K Smith

引用次数: 0

Phase II study on oral N-methylformamide in metastatic colorectal cancer. 口服n -甲基甲酰胺治疗转移性结直肠癌的II期研究。

Cancer treatment reports Pub Date : 1987-12-01

A S Planting, J G Klijn, J Verweij, G Stoter

引用次数: 0

Distribution of clomesone in mice. 克隆体在小鼠体内的分布。

Cancer treatment reports Pub Date : 1987-12-01

P E Noker, D L Hill

{"title":"Distribution of clomesone in mice.","authors":"P E Noker, D L Hill","doi":"","DOIUrl":"","url":null,"abstract":"The distribution of the novel alkylating agent clomesone [2-chloroethyl (methylsulfonyl)-methane sulfonate] has been studied in mice after iv administration of 35 mg/kg. In plasma, [14C]clomesone was eliminated in an apparent single phase with a half-life of 11 minutes. The elimination of total radioactivity occurred with an initial half-life of 51 minutes, and then in prolonged phase of undetermined length. At least two organic soluble metabolites were detectable in plasma. Highest tissue concentrations of radioactivity were in liver, kidney, and small intestines where, at most times of analysis, the levels were two to three times higher than those in plasma. The rate of elimination of radiolabel from spleen, lungs, brain, and muscle, which contained about equal concentrations of radioactivity at most times after dosing, paralleled the rate of loss from plasma. A major proportion of the radioactivity in tissues was bound to trichloracetic acid-precipitable macromolecules. Within 24 hours, 77.6% of the dose was recovered in urine. High-pressure liquid chromatographic analyses of 8-hour urine collections demonstrated that less than 2% of the dose was excreted unchanged. These results demonstrate that clomesone is rapidly eliminated from plasma and that it and/or its products become extensively bound to tissue components.","PeriodicalId":9581,"journal":{"name":"Cancer treatment reports","volume":"71 12","pages":"1135-40"},"PeriodicalIF":0.0,"publicationDate":"1987-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"13963415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Phase II study of lonidamine in patients with small cell carcinoma of the lung. lonidamine治疗肺小细胞癌的II期研究。

Cancer treatment reports Pub Date : 1987-12-01

N Murray, A Shah, P Band

引用次数: 0

Phase II trial of mitoxantrone as first-line chemotherapy for extensive small cell lung cancer. 米托蒽醌作为广泛小细胞肺癌一线化疗的II期试验。

Cancer treatment reports Pub Date : 1987-12-01

S T Malik, H Rayner, J Fletcher, M L Slevin

引用次数: 0

Phase II trial of etoposide in the management of advanced and recurrent leiomyosarcoma of the uterus: a Gynecologic Oncology Group Study. 依托泊苷治疗晚期和复发性子宫平滑肌肉瘤的II期试验:一项妇科肿瘤组研究。

Cancer treatment reports Pub Date : 1987-12-01

R E Slayton, J A Blessing, C Angel, M Berman